The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1336
Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Fentanyl buccal soluble film (Onsolis – Meda) has been approved by the FDA for treatment of breakthrough pain in adult cancer patients who are already taking and are tolerant to around-the-clock opioid therapy. It is designated as a Schedule II controlled substanceTwo other oral transmucosal formulations of fentanyl are already available for this indication.1,2

ADMINISTRATIONOnsolis uses a drug delivery technology called BioErodible MucoAdhesive (BEMA). It is packaged as a dime- or nickel-sized film with a white side that identifies the dosage strength, and a pink side that contains the active ingredient. The pink side is placed against the inside of the moistened cheek, held for 5 seconds and then left in place. The patient can drink liquids after 5 minutes, but should avoid food until the film dissolves (usually 15-30 minutes). Tearing, chewing or swallowing the film can ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fentanyl Buccal Soluble Film (Onsolis) for Breakthrough Cancer Pain
Article code: 1336c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian